Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
Authors
Keywords
-
Journal
Cancer Communications
Volume 39, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-30
DOI
10.1186/s40880-019-0399-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients
- (2018) Chiara Baratelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls
- (2017) Lilin He et al. OncoTargets and Therapy
- RRM1*151A>T,RRM1-756T>C, andRRM1-585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
- (2016) Xiao-Ling Xu et al. Cancer Medicine
- Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
- (2015) Christoph Zielinski et al. BRITISH JOURNAL OF CANCER
- Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case–control studies
- (2015) Shu-Zhe Xie et al. TUMOR BIOLOGY
- A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS
- (2014) Dan Rosmarin et al. GUT
- Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2014) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
- (2014) Dan Rosmarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials
- (2014) Hans-Joachim Schmoll et al. LANCET ONCOLOGY
- Association of 677 C>T (rs1801133) and 1298 A>C (rs1801131) Polymorphisms in the MTHFR Gene and Breast Cancer Susceptibility: A Meta-Analysis Based on 57 Individual Studies
- (2014) Kai Li et al. PLoS One
- Association between MTHFR C677T polymorphism and thyroid cancer risk: a meta-analysis
- (2014) Yulan Yan et al. TUMOR BIOLOGY
- Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
- (2013) A Loganayagam et al. BRITISH JOURNAL OF CANCER
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)
- (2013) Bulent Cetin et al. JOURNAL OF CHEMOTHERAPY
- Systematic identification of trans eQTLs as putative drivers of known disease associations
- (2013) Harm-Jan Westra et al. NATURE GENETICS
- Significant Association between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer
- (2012) Yuichiro Azuma et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
- (2011) A. G. Pallis et al. ANNALS OF ONCOLOGY
- A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome
- (2011) D. Caronia et al. CLINICAL CANCER RESEARCH
- Survival differences among women with de novo stage IV and relapsed breast cancer
- (2010) S. Dawood et al. ANNALS OF ONCOLOGY
- A map of human genome variation from population-scale sequencing
- (2010) Richard M. Durbin et al. NATURE
- MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
- (2009) S. Afzal et al. ANNALS OF ONCOLOGY
- Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
- (2009) M Gusella et al. BRITISH JOURNAL OF CANCER
- A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
- (2008) N. Ribelles et al. CURRENT DRUG METABOLISM
- Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
- (2008) Matthias Schwab et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started